Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 6 peer-reviewed journal articles Updated
Neurology

Understanding Your APBD Diagnosis

At a Glance

APBD is a rare, slowly progressive neurological disorder caused by disease-causing variants in both copies of the GBE1 gene. Symptoms often begin in adulthood, and their severity and rate of progression vary, so regular follow-up and genetic counseling can help patients and families plan care.

Finding out you have Adult Polyglucosan Body Disease (APBD) often comes after years of searching for answers. Because it is an ultra-rare condition, many people spend years visiting different specialists before the correct diagnosis is made [1][2]. Receiving this news can be overwhelming, but understanding the underlying science, how the condition is inherited, and the typical patterns of the disease can help you navigate what comes next.

What is APBD?

APBD is a genetic, slowly progressive metabolic disorder. It is caused by mutations in the GBE1 gene, which provides instructions for making the glycogen branching enzyme [3]. This enzyme is responsible for giving glycogen (the stored form of sugar your body uses for energy) its proper branched structure.

In APBD, this enzyme doesn’t work correctly. Without proper branching, the glycogen becomes insoluble and forms stiff clumps called polyglucosan bodies [4]. These bodies build up over time inside the cells of your nervous system, eventually interfering with the way nerves send signals to your muscles and organs [1].

Inheritance and Family Planning

APBD is an autosomal recessive condition [2]. This means that for a person to develop the disease, they must inherit two disease-causing mutations (variants) in the GBE1 gene—one from each parent. These are called biallelic variants.

  • Carriers: A person with only one GBE1 mutation is a “carrier.” Carriers typically do not have symptoms of APBD.
  • Family Risk: If you have APBD, your siblings have a 25% chance of also having inherited two variants (if both your parents were carriers). Your children will inherit one of your variants, making them carriers. They will only develop the disease if your partner is also a carrier and passes down a second variant.
  • Genetic counseling is highly recommended for you and your family to understand these specific risks, especially if you have a “variant of uncertain significance” or if standard testing only found one mutation [5].

The Diagnostic Journey

Most people with APBD do not notice symptoms until their 50s or 60s [2]. Because these symptoms—such as frequent urination, walking difficulties, or numbness in the feet—can look like many other conditions, a diagnostic delay is common.

  • Typical Onset: Symptoms often begin around age 51 [2].
  • The Delay: In a 96-person registry, the median age of diagnosis was 57 years, meaning many patients waited about six or seven years for an accurate diagnosis [2].
  • Misdiagnosis: It is common for patients to be diagnosed with more common conditions first, such as peripheral neuropathy (nerve damage), spinal stenosis (narrowing of the spinal canal), prostate issues, or even multiple sclerosis (MS) [1][2].

APBD and Glycogen Storage Disease Type IV

You may hear APBD referred to as a “form” of Glycogen Storage Disease Type IV (GSD IV). While they share the same genetic cause (the GBE1 gene), they are not exactly the same in how they affect people:

  • The GSD IV Spectrum: GSD IV is a broad category of disorders. Some forms are extremely severe and affect infants’ livers or hearts [3].
  • The APBD Phenotype: APBD is specifically the adult-onset, neurological version of this spectrum. It primarily affects the brain, spinal cord, and peripheral nerves [4].
  • A Rarity Within a Rarity: Because APBD is often grouped together with all GSD IV cases in medical databases, its exact prevalence is hard to pin down. A recent genetic model estimated that the global carrier frequency for the entire GSD IV spectrum leads to a genetic prevalence of about 1 in 235,000 people [3]. APBD itself is just a subset of this, making it even rarer. These broad estimates should not be used to predict the exact number of APBD cases in your community.

Understanding Your Progression

One of the most important things to know about APBD is its heterogeneity—the disease progresses differently in every person. While it is generally a slowly progressive condition, limited natural history studies have shown that your “baseline” (your physical state at the time of diagnosis) may offer some clues:

  • Variable Stability: In a small, 23-patient observational study, patients who had mild symptoms at the time of diagnosis often remained relatively stable for up to four years [6].
  • Progression: In the same study, patients who already had significant difficulty walking at baseline experienced a more noticeable decline over that four-year period [6].
  • These are group-level observations, not strict rules for your personal future. The amount of “residual” (leftover) enzyme activity in your body and your specific genetic variants may play a role in how the disease moves [4].

While the genetic mechanism is well-understood, much is still being learned. Being proactive with your care team and regularly monitoring your functional status can help you make the best decisions for your quality of life.

Common questions in this guide

What causes adult polyglucosan body disease (APBD)?
APBD is caused by disease-causing variants in both copies of the GBE1 gene. These variants reduce the activity of the glycogen branching enzyme, allowing abnormal, insoluble glycogen deposits called polyglucosan bodies to build up in nervous-system cells.
How is APBD inherited, and what does it mean for my family?
APBD follows an autosomal recessive inheritance pattern, so a person usually needs one disease-causing GBE1 variant from each parent. Someone with one variant is usually an unaffected carrier, while a person with APBD passes one variant to each child; a child would develop APBD only if the other parent also carries and passes on a disease-causing variant. A genetic counselor can explain risks for siblings, children, and partners.
What symptoms are common at the start of APBD?
Symptoms often begin in the 50s or 60s and may include frequent urination, bladder changes, difficulty walking, tripping, and numbness in the feet. These symptoms can resemble more common conditions, which is one reason diagnosis may be delayed.
Why can it take so long to diagnose APBD?
APBD is ultra-rare, and its early symptoms overlap with peripheral neuropathy, spinal stenosis, prostate problems, and multiple sclerosis. Many people see several specialists and receive another diagnosis before genetic testing or other evaluation identifies APBD.
Is APBD the same as Glycogen Storage Disease Type IV?
APBD is the adult-onset neurological form within the broader GSD IV spectrum, and both are related to GBE1 variants. Other GSD IV forms can be severe in infancy and affect organs such as the liver or heart, so the terms are related but do not describe identical disease patterns.
Can doctors predict how quickly APBD will progress?
APBD usually progresses slowly, but its course varies from person to person. Small observational studies suggest that people with mild symptoms at diagnosis may remain relatively stable for several years, while those with substantial walking difficulty may decline more noticeably; these group observations cannot predict an individual’s future.
What testing can confirm APBD if only one GBE1 variant is found?
A diagnosis generally depends on identifying disease-causing variants in both copies of GBE1. If testing finds only one variant or a variant of uncertain significance, your clinician may discuss additional testing, such as deletion/duplication analysis, and genetic counseling.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my genetic testing confirm that I have biallelic variants (mutations on both copies of the GBE1 gene), or do we need further testing like deletion/duplication analysis?
  2. 2.Based on my current mobility and symptoms, what baseline assessments should we perform to track my individual disease course?
  3. 3.Do I have any signs of liver, heart, or muscle involvement that might suggest a broader Glycogen Storage Disease Type IV phenotype?
  4. 4.Given the rarity of APBD, how many other patients with this condition do you or this center currently manage?
  5. 5.Can you refer me and my family to a genetic counselor to discuss the risks for my siblings or children?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (6)
  1. 1

    Frequent misdiagnosis of adult polyglucosan body disease.

    Hellmann MA, Kakhlon O, Landau EH, et al.

    Journal of neurology 2015; (262(10)):2346-51 doi:10.1007/s00415-015-7859-4.

    PMID: 26194201
  2. 2

    A United States-based patient-reported adult polyglucosan body disease registry: initial results.

    Sparks J, Michelassi F, Thompson JLP, et al.

    Therapeutic advances in rare disease 2024; (5()):26330040241227452 doi:10.1177/26330040241227452.

    PMID: 38445267
  3. 3

    Unifying the Communities of Early-Onset Glycogen Storage Disease Type IV and Adult Polyglucosan Body Disease Through a Genetic Prevalence Study of GBE1-Related Disease.

    Koch RL, Akman HO, Chown E, et al.

    JIMD reports 2026; (67(3)):e70080 doi:10.1002/jmd2.70080.

    PMID: 41948007
  4. 4

    A novel mouse model that recapitulates adult-onset glycogenosis type 4.

    Orhan Akman H, Emmanuele V, Kurt YG, et al.

    Human molecular genetics 2015; (24(23)):6801-10 doi:10.1093/hmg/ddv385.

    PMID: 26385640
  5. 5

    Case report: Expanding the understanding of the adult polyglucosan body disease continuum: novel presentations, diagnostic pitfalls, and clinical pearls.

    Gayed MM, Sgobbi P, Pinto WBVR, et al.

    Frontiers in genetics 2023; (14()):1282790 doi:10.3389/fgene.2023.1282790.

    PMID: 38164512
  6. 6

    A double-blind, placebo-controlled trial of triheptanoin in adult polyglucosan body disease and open-label, long-term outcome.

    Schiffmann R, Wallace ME, Rinaldi D, et al.

    Journal of inherited metabolic disease 2018; (41(5)):877-883 doi:10.1007/s10545-017-0103-x.

    PMID: 29110179

This page explains APBD inheritance, diagnosis, and progression for informational purposes only and does not constitute medical advice. Your care team and a genetic counselor can help interpret your results and plan care.

Get notified when new evidence is published on Adult polyglucosan body disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.